Effect of switching drug formulations from immediate-release to extended-release oros methylphenidate: A chart review of Spanish adults with attention-deficit hyperactivity disorder

CNS Drugs

Volumn 22, Issue 7, 2008, Pages 603-611

  Ramos Quiroga, Josep Antoni ^a,b   Bosch, Rosa ^a   Castells, Xavier ^a   Valero, Sergi ^a   Nogueira, Mariana ^a   Gómez, Nuria ^a   Yelmo, Silvia ^a   Ferrer, Marc ^a,b   Martínez, Yolanda ^a   Casas, Miguel ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Attention deficit hyperactivity disorder, treatment; Central nervous system stimulants, therapeutic use; Controlled release drugs; Methylphenidate, adverse reactions; Methylphenidate, therapeutic use; Patient compliance

Indexed keywords

METHYLPHENIDATE; RUBIFEN;

ABDOMINAL DISEASE; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DECREASED APPETITE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL INSTABILITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; TABLET FORMULATION; TACHYCARDIA; XEROSTOMIA;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSION PUMPS, IMPLANTABLE; MALE; METHYLPHENIDATE; OUTPATIENTS; RETROSPECTIVE STUDIES; SPAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 45249093653     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200822070-00005     Document Type: Article

References (35)

1. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005; 366 (9481): 237-48
2. Faraone SV, Biederman J. What is the prevalence of adult ADHD? Results of a population screen of 966 adults. J Atten Disord 2005; 9 (2): 384-91
3. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007 May; 190: 402-9
4. Kooij JJ, Buitelaar JK, van den Oord EJ, et al. Internal and external validity of attention-deficit hyperactivity disorder in a population-based sample of adults. Psychol Med 2005 Jun; 35 (6): 817-27
5. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006; 163 (4): 716-23
6. Biederman J, Faraone SV. The effects of attention-deficit/hyperactivity disorder on employment and household income. MedGenMed 2006; 8 (3): 12
7. Barkley RA, Murphy KR, Kwasnik D. Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics 1996 Dec; 98 (6 Pt 1): 1089-95
8. Schubiner H, Tzelepis A, Milberger S, et al. Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. J Clin Psychiatry 2000 Apr; 61 (4): 244-51
9. Schachter HM, Pham B, King J, et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 2001; 165 (11): 1475-88
10. Faraone SV, Biederman J. Efficacy of Adderall for attention-deficit/ hyperactivity disorder: a meta-analysis. J Atten Disord 2002 Sep; 6 (2): 69-75
11. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41 (2 Suppl.): 26-49S
12. Kooij JJ, Burger H, Boonstra AM, et al. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder: a randomized placebo-controlled double-blind cross-over trial. Psychol Med 2004 Aug; 34 (6): 973-82
13. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57 (5): 456-63
14. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006; 59 (9): 829-35
15. Reimherr FW, Williams ED, Strong RE, et al. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 2007 Jan; 68 (1): 93-101
16. Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/ hyperactivity disorder: overview of the evidence. Pediatrics 2005 Jun; 115 (6): e749-57
17. Swanson J. Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement. CNS Drugs 2003; 17 (2): 117-31
18. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001 Aug; 23 (8): 1296-310
19. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353 (5): 487-97
20. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics 2001 Oct; 108 (4): 883-92
21. McGough JJ, McBurnett K, Bukstein O, et al. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2006 Jun; 16 (3): 351-6
22. Steele M, Weiss M, Swanson J, et al. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in atten-tion deficit-hyperactivity disorder. Can J Clin Pharmacol 2006; 13 (1): e50-62
23. Lage M, Hwang P. Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and out-comes of treatment. J Child Adolesc Psychopharmacol 2004; 14 (4): 575-81
24. Sanchez RJ, Crismon ML, Barner JC, et al. Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy 2005 Jul; 25 (7): 909-17
25. Hoare P, Remschmidt H, Medori R, et al. 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. Eur Child Adolesc Psychiatry 2005 Sep; 14 (6): 305-9
26. Epstein J, Johnson D, Conners CK. Conners adult ADHD diagnostic interview for DSM-IV. North Tonawanda (NY): Multi-Health Systems, 1999
27. First MB, Spitzer RL, Gibbon M, et al. Structured clinical interview for DSM-IV axis I disorders-clinician version (SCID-CV). Washington, DC: American Psychiatric Press, Inc., 1997
28. First MB, Gibbon M, Spitzer RL, et al. Structured clinical interview for DSM-IV axis II personality disorders (SCID-II). Washington, DC: American Psychiatric Press, Inc., 1997
29. Faraone SV, Spencer T, Aleardi M, et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2004; 24 (1): 24-9
30. Concerta® (methylphenidate HCl) extended-release tablets CII [online]. Available from URL: http://www.fda.gov/cder/foi/label/2007/ 021121s014lbl.pdf. [Accessed 2007 Nov 12]
31. DuPaul GJ. ADHD rating scale-IV: checklists, norms, and clin-ical interpretation. New York: Guilford Press, 1998
32. Guy W. Early Clinical Drug Evaluation (ECDEU) assessment manual. Rockville (MD): National Institute of Mental Health, 1976
33. Knobel H, Alonso J, Casado JL, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. Aids 2002; 16 (4): 605-13
34. Spencer T, Wilens T, Biederman J, et al. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995 Jun; 52 (6): 434-43
35. Biederman J, Mick EO, Surman C, et al. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry 2007; 7: 49